NEW YORK, NY--(Marketwire - Jan 9, 2012) - Biotechnology stocks have performed well in the early stages of the New Year. Last Thursday, the NYSE Arca Biotechnology Index skyrocketed as much as 3 percent, reaching a two-month intraday high. With several potential blockbuster drugs working their way through the approval process this year, 2012 could be a big year for biotech. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Human Genome Sciences, Inc. (NASDAQ: [ HGSI ]) and Oncothyreon Inc. (NASDAQ: [ ONTY ]). Access to the full company reports can be found at:

[ www.fivestarequities.com/HGSI ]

[ www.fivestarequities.com/ONTY ]

Human Genome Sciences, Inc. operates as a biopharmaceutical company. Its principal products in development include BENLYSTA for systemic lupus erythematosus. Last month Human Genome Sciences and GlaxoSmithKline announced that dosing has been initiated in BLISS-SC, a new Phase 3 trial to evaluate the efficacy, safety and tolerability of BENLYSTA, belimumab, administered subcutaneously once-weekly.

In addition, HGSI holds financial rights to certain products in the GlaxoSmithKline clinical development pipeline, including darapladib, a Phase III clinical trial product for the treatment of coronary heart disease and ischemic stroke.

Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at [ www.fivestarequities.com ] and get exclusive access to our numerous stock reports and industry newsletters.

Oncothyreon focuses on the development of therapeutic products for the treatment of cancer. Last month Oncothyreon announced the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for ONT-10, a therapeutic vaccine directed at cancers expressing MUC1.

Oncothyreon says that preclinical results demonstrated that "administration of ONT-10 produces a robust antibody response in mice specific for human tumor MUC1. A strong cellular immune response directed to the target was also shown."

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: [ www.fivestarequities.com/disclaimer ]